title: A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
authors.forename: Kami
authors.initials: K
authors.lastname: Maddocks
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
authors.forename: Erin
authors.initials: E
authors.lastname: Hertlein
authors.affiliation: b Comprehensive Cancer Center, The Ohio State University , Columbus , OH , USA ;
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Chen
authors.affiliation: b Comprehensive Cancer Center, The Ohio State University , Columbus , OH , USA ;
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Wagner
authors.affiliation: c Division of Pharmaceutics , College of Pharmacy, The Ohio State University , Columbus , OH , USA ;
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Ling
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
authors.forename: Joseph
authors.initials: J
authors.lastname: Flynn
authors.affiliation: c Division of Pharmaceutics , College of Pharmacy, The Ohio State University , Columbus , OH , USA ;
authors.forename: Mitch
authors.initials: M
authors.lastname: Phelps
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Johnson
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;|d Division of Medicinal Chemistry , College of Pharmacy, The Ohio State University , Columbus , OH , USA.
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.affiliation: a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Jones
mesh_terms: D000368:Aged; D016227:Benzoquinones / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007275:Injections, Intravenous; D047029:Lactams, Macrocyclic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D012008:Recurrence
chemical_list: D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C448659:17-(dimethylaminoethylamino)-17-demethoxygeldanamycin